DISEASE MANAGEMENT
Imiglucerase
What is imiglucerase?
Imiglucerase is an intravenous enzyme replacement therapy for Gaucher disease.
INTRODUCING
Taliglucerase alfa
The introduction of enzyme replacement therapy and substrate reduction therapy has enhanced the management of Gaucher disease.
Taliglucerase alfa is an intravenous enzyme replacement therapy for Gaucher disease.1 The mechanism of action of taliglucerase alfa is presented in Figure 1. For further information on taliglucerase alfa, please consult your local prescribing information.
Figure 1.
Mechanism of action of taliglucerase alfa1,2
C-ANPROM/INT//7568; Date of preparation: September 2020
- Pfizer Canada Inc. ELELYSO® Product Monograph. Last updated August 2017.
- Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18: 441.
DISEASE MANAGEMENT
Velaglucerase alfa
What is velaglucerase alfa?
Velaglucerase alfa is an intravenous enzyme replacement therapy for Gaucher disease.
DISEASE MANAGEMENT
Enzyme replacement therapy
What enzyme replacement therapies are available for Gaucher disease?
Three long-term enzyme replacement therapies are available for patients with Gaucher disease: imiglucerase, velaglucerase alfa and taliglucerase.
Register
Registration gives the benefit of site update emails and additional information on new education materials and events